Per Malmström
81 – 100 of 157
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2008
-
Mark
Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast conservation surgery with or without postoperative radiotherapy
(
- Contribution to journal › Article
-
Mark
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
2008) EBCC-6, European Breast Cancer Conference, 2008 In European Journal of Cancer Supplements 6(7). p.116-117(
- Contribution to journal › Published meeting abstract
-
Mark
Tiling array-CGH for the assessment of genomic similarities among synchronous unilateral and bilateral invasive breast cancer tumor pairs.
(
- Contribution to journal › Article
-
Mark
Establishment and implementation of common guidelines for 3D treatment planning for breast cancer in southern and western Sweden
(
- Contribution to journal › Published meeting abstract
-
Mark
SORENESS AND SENSITIVITY TO SUN EXPOSURE 10 TO 16 YEARS AFTER BREAST CANCER RADIOTHERAPY
(
- Contribution to journal › Published meeting abstract
-
Mark
Multizentrische Studien zur Postoperativen Strahlentherapie Niedriggradiger Astrozytome und Oligodendrogliome
(
- Contribution to journal › Article
- 2007
-
Mark
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity
(
- Contribution to journal › Article
-
Mark
Radiotherapy and tamoxifen after mastectomy in postmenopausal women - 20 year follow-up of the South Sweden Breast Cancer group randomised trial SSBCG II : I
(
- Contribution to journal › Article
-
Mark
Estrogen receptor beta expression is associated with tamoxifen response in ER alpha-negative breast carcinoma
(
- Contribution to journal › Article
-
Mark
Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy
(
- Contribution to journal › Article
- 2006
-
Mark
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401.
(
- Contribution to journal › Article
-
Mark
Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer
(
- Contribution to journal › Article
-
Mark
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
(
- Contribution to journal › Article
-
Mark
Time dependent effects of tamoxifen treatment on cardiovascular morbidity
(
- Contribution to journal › Published meeting abstract
- 2005
-
Mark
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
(
- Contribution to journal › Published meeting abstract
-
Mark
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial
(
- Contribution to journal › Article
-
Mark
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(
- Contribution to journal › Article
-
Mark
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
(
- Contribution to journal › Article
-
Mark
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(
- Contribution to journal › Article
-
Mark
Estrogen receptor (ER)-beta has favorable independent prognostic value for ER-alfa negative breast cancer patients receiving adjuvant tamoxifen
(
- Contribution to journal › Published meeting abstract